Tin tức & Cập nhật

The Janus kinase inhibitor upadacitinib induces significantly higher response than placebo in ankylosing spondylitis patients with inadequate response to biological disease-modifying antirheumatic drugs, without introducing new safety signals, according to data from a phase III trial.

A time-limited regimen of venetoclax plus obinutuzumab with or without ibrutinib improved progression-free survival (PFS) in fit, treatment-naïve patients with chronic lymphocytic leukaemia (CLL), according to results of the phase III GAIA/CLL13 trial presented at EHA 2022.

Treatment with dextromethorphan-bupropion (AXS-05) significantly improves depressive symptoms relative to bupropion alone and is well tolerated in patients with major depression, results of a phase II trial have shown.

Treatment with the next-generation anti-TNFα antibody yields marked improvements in the signs and symptoms of rheumatoid arthritis in patients with inadequate response to methotrexate (MTX), while having an acceptable safety profile, as shown in the phase II/III OHZORA trial.

Taking aspirin daily appears to do nothing in terms of reducing the risk of cutaneous melanoma in older individuals, according to a study.

Treatment with intravenous or oral solithromycin is well-tolerated and leads to clinical improvement in most children and adolescents with community-acquired bacterial pneumonia (CABP), results of a recent study have shown.

The serine protease inhibitor camostat mesylate does not appear to be an effective antiviral agent in patients with early-phase COVID-19, having failed to stop SARS-CoV-2 in its tracks in a phase II trial.

Just as the world adapts to a new normal after the COVID-19 pandemic, a new outbreak of a not-so-new virus has been making headlines. But why the sudden concern?